Status:
UNKNOWN
Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy
Lead Sponsor:
Karolinska University Hospital
Collaborating Sponsors:
AstraZeneca
Conditions:
Diabetes, Type I
Eligibility:
All Genders
17-30 years
Phase:
PHASE4
Brief Summary
The type 1 diabetes patients who were still normoalbuminuric and normotensive, after 17 years duration and a second research kidney biopsy, could enter the double blind treatment study of Atacand or P...
Detailed Description
46 patients performed a first kidney biopsy between 1992-1994. After 6 years 29 accepted to perform a second biopsy. During the follow-up 10 patients developed complications i.e. hypertension or micro...
Eligibility Criteria
Inclusion
- Diabetes type 1 patient
- Normotensive
- Normoalbuminuric
- Signed informed consent
- Female and male
- Over 17 years of age
- Diabetes duration over 10 years
Exclusion
- Hypertension
- Microalbuminuria
- Pregnancy
- Lactation
- Reduced kidney function
- Artery stenosis
- Kidney transplantation
- Allergy to the medication in the study
- Reduced liver function
- Alcohol or drug abuse
- Participation in another drug or clinical test during last 30 days
- Severe diseases i.e. malignancy
- Previously enrolment of the present study
Key Trial Info
Start Date :
September 1 2000
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00328302
Start Date
September 1 2000
End Date
April 1 2006
Last Update
May 19 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Childrens Hospital, Karolinska University Hospital, Huddinge
Stockholm, Sweden, 141 86